CME/CNE/CPE Medical Education Program Helps Physicians Integrate the FDA Mycophenolate Safety Standards to Prevent Potential Birth Defects
November, 2021; Columbia, Maryland. Leading continuing medical education provider, Rockpointe, in conjunction with Boston University and Potomac Center for Medical Education is offering webinars and an on-demand web course on mycophenolate safety standards to help prevent birth defects when prescribing mycophenolic acid (MPA) products, including mycophenolate mofetil (MMF) (CellCept) and enteric-coated mycophenolate sodium (Myfortic). This continuing medical education program is offered free of charge to all clinicians who prescribe mycophenolates.
Mycophenolates were approved by the FDA in 1995 and 2004, respectively, as immunosuppressants used in preventing rejection of transplanted organs. MPA has become a front-line anti-rejection therapy in combination with calcineurin-inhibitors and corticosteroids in addition mycophenolate’s are widely used in the treatment of a wide range of autoimmune conditions such as lupus, rheumatoid arthritis and multiple sclerosis.
However, use of MPA during pregnancy is associated with a significant increased risk of pregnancy loss, congenital malformations, and low birth weight. The FDA approved the Mycophenolate Shared System Risk Evaluation and Mitigation Strategy (MREMS) in 2012, but despite the information provided to clinicians and patients on the pregnancy risks associated with the use of MPA, pregnancies are still occurring too frequently in patients being treated with MPAs leading to preventable adverse pregnancy outcomes.
Integrating the FDA Mycophenolate Safety Standards to Prevent Adverse Pregnancy Outcomes will provide HCPs who prescribe MPAs with information on MPA-associated pregnancy risks, the need for counseling female patients of reproductive potential on birth control and planning, and the need for reporting pregnancies to the Mycophenolate Pregnancy Registry. It will also provide information to female patients of reproductive potential who are prescribed MPA about the pregnancy risks and the importance of appropriate planning and birth control.
A live webinar is scheduled for:
Monday, November 8, 2021
8:30 – 9:30 PM ET (7:30 – 8:30 PM CT / 6:30 – 7:30 PM MT / 5:30 – 6:30 PM PT)
For more information and to register for this activity, click here.
An on-demand webcourse will be available on www.rockpointe.com in the near future.
Continuing Medical Education (ACCME) is provided through the joint providership of, Boston University Medical Center, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™ and the American Nurses Credentialing Center (ANCC) Boston University designates this activity for a maximum of 1 ANCC contact hour to provide 1 contact hour and, the Potomac Center for Medical Education (PCME) accredited the Accreditation Council for Pharmacy Education (ACPE), to provide continuing education for the healthcare team.
Successful completion of this CME program, which includes participation in the evaluation component, enables participants to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Completion of this accredited CME activity also meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
There is no fee for this activity, which is supported by an independent medical education grant from the Mycophenolate REMS committee. To receive credit, participants must register, view the CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
